• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sidoti's November Micro-Cap Virtual Conference

    11/8/22 3:40:00 PM ET
    $CGRN
    $DPSI
    $FGI
    $GIFI
    Industrial Machinery/Components
    Industrials
    Computer Software: Programming Data Processing
    Technology
    Get the next $CGRN alert in real time by email
    • Presentation Times and Weblinks Released for Over 35 Presenting Companies
    • Wednesday and Thursday, November 9-10, 2022

    NEW YORK, NY / ACCESSWIRE / November 8, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 9-10, 2022. The links can also be found at www.sidoticonference.com/events .

    Sidoti & Company, LLC, Tuesday, November 8, 2022, Press release picture

    Presentation Agenda

    Wednesday, November 9th, 2022 (Day 1)

    9:15-9:45

    Bel Fuse (BELFB)

    Splash Beverage Group (SBEV)

    Generation Income Properties (GIPR)

    10:00-10:30

    *****

    Miromatrix Medical Inc. (MIRO)

    FRX Innovations (FRXI)

    10:45-11:15

    Guerrilla RF (GUER)

    CVG (CVGI)

    EzFill Holdings (EZFL)

    11:30-12:00

    CareCloud (MTBC)

    Mistras Group (MG)

    *****

    12:15-12:45

    Civeo Corporation (CVEO)

    XORTX Therapeutics, Inc. (XRTX)

    Mill City Ventures III (MCVT)

    1:00-1:30

    *****

    Blue Star Foods (BSFC)

    Argentina Lithium & Energy (PNXLF)

    1:45-2:15

    *****

    Akari Therapeutics (AKTX)

    Conifex Timber Inc. (CFF)

    2:30-3:00

    Ascent Industries Co. (ACNT)

    Transcode (RNAZ)

    Ashford Hospitality Trust (AHT)

    3:15-3:45

    Heartcore Enterprises, Inc. (HTCR)

    Electromed, Inc. (ELMD)

    *****

    4:00-4:30

    ShiftPixy, Inc. (PIXY)

    Propanc Biopharma Inc. (PPCB)

    *****

    1x1s Only

    Quanex Building Products (NX)

    Thursday, November 10th, 2022 (Day 2)

    9:15-9:45

    SmartKem (SMTK)

    TARENA International (TEDU)

    *****

    10:00-10:30

    *****

    Loop Industries (LOOP)

    *****

    10:45-11:15

    TESSCO Technologies (TESS)

    *****

    *****

    11:30-12:00

    DecisionPoint Systems (DPSI)

    *****

    Independence Contract Drilling (ICD)

    12:15-12:45

    Boardwalktech Software (BWLKF)

    HOOKIPA Pharma Inc. (HOOK)

    *****

    1:00-1:30

    SOBR Safe Inc (SOBR)

    MAIA Biotechnology, Inc. (MAIA)

    Capstone Green Energy (CGRN)

    1x1s Only

    FGI Industries (FGI) | Gulf Island Fabrication (GIFI)

    About Sidoti
    For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on Small Cap and Micro-Cap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a Small Cap and Micro-Cap focused nationwide sales effort, and broad access to corporate management teams. We serve 500+ institutional clients in the U.S. and Canada, including many leading institutional managers. Sidoti promotes meaningful interaction between issuers and investors in the Small Cap and Micro-Cap space through a series of investor conferences ( www.sidoti.com/events ) we host each year.

    CONTACT
    Sidoti Events Team
    212-453-7031
    conference@sidoti.com

    SOURCE: Sidoti & Company, LLC



    View source version on accesswire.com:
    https://www.accesswire.com/724582/Sidotis-November-Micro-Cap-Virtual-Conference

    Get the next $CGRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGRN
    $DPSI
    $FGI
    $GIFI

    CompanyDatePrice TargetRatingAnalyst
    HOOKIPA Pharma Inc.
    $HOOK
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    HOOKIPA Pharma Inc.
    $HOOK
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    Gulf Island Fabrication Inc.
    $GIFI
    3/8/2024Hold → Accumulate
    Johnson Rice
    Loop Industries Inc.
    $LOOP
    12/29/2022Buy → Neutral
    H.C. Wainwright
    HOOKIPA Pharma Inc.
    $HOOK
    12/2/2022Neutral → Underperform
    BofA Securities
    Independence Contract Drilling Inc.
    $ICD
    3/22/2022$7.00Hold → Buy
    Johnson Rice
    FGI Industries Ltd.
    $FGI
    2/23/2022$7.00Outperform
    Northland Capital Markets
    HOOKIPA Pharma Inc.
    $HOOK
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

    12/20/24 7:37:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

    RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

    11/15/24 11:07:50 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gulf Island Fab upgraded by Johnson Rice

    Johnson Rice upgraded Gulf Island Fab from Hold to Accumulate

    3/8/24 11:07:40 AM ET
    $GIFI
    Metal Fabrications
    Industrials

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

    Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing protocols CHICAGO, June 03, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared an amendment to update its investigational new drug (IND) application which enables MAIA to open U.S. enrollment for the expansion of the Phase 2 THIO-101 trial of its lead candidate, ateganosine, as

    6/3/26 9:45:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces Open Market Purchases by CEO and Director

    CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan V. Smith, Ph.D. have increased their ownership positions through open market purchases. Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an average common stock price of $1.3877. Approximately 75,000 shares of MAIA common stock were purchased by Dr. Smith on June 6, 2026, at an average common stock price of $1.336. "Our continuing investments underscore our stron

    6/2/26 9:45:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

    CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, delivered a poster presentation on May 31, 2026, featuring the methodology and study design for its pivotal Phase 3 clinical trial (THIO-104) at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO 2026), being held May 29 – June 2, 2026, in MAIA's home city of Chicago, Illinois. THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC)

    6/1/26 8:00:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Vitoc Vlad bought $100,886 worth of shares (72,700 units at $1.39), increasing direct ownership by 8% to 976,121 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:02:16 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $100,200 worth of shares (75,000 units at $1.34) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:01:25 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Gryaznov Sergei bought $2,690 worth of shares (2,000 units at $1.34), increasing direct ownership by 4% to 46,511 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:00:31 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Vitoc Vlad bought $100,886 worth of shares (72,700 units at $1.39), increasing direct ownership by 8% to 976,121 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:02:16 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $100,200 worth of shares (75,000 units at $1.34) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:01:25 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Gryaznov Sergei bought $2,690 worth of shares (2,000 units at $1.34), increasing direct ownership by 4% to 46,511 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/2/26 9:00:31 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    SEC Filings

    View All

    FGI Industries Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - FGI Industries Ltd. (0001864943) (Filer)

    6/3/26 4:50:37 PM ET
    $FGI
    Industrial Specialties
    Industrials

    SEC Form 10-K filed by Loop Industries Inc.

    10-K - Loop Industries, Inc. (0001504678) (Filer)

    5/27/26 4:31:13 PM ET
    $LOOP
    Major Chemicals
    Industrials

    SEC Form PRE 14A filed by Loop Industries Inc.

    PRE 14A - Loop Industries, Inc. (0001504678) (Filer)

    5/27/26 4:30:39 PM ET
    $LOOP
    Major Chemicals
    Industrials

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

    SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 6:16:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MAIA Biotechnology Inc.

    SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 5:12:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Financials

    Live finance-specific insights

    View All

    FGI INDUSTRIES ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

    EAST HANOVER, N.J., April 9, 2026 /PRNewswire/ -- FGI Industries Ltd. (NASDAQ:FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced results for the fourth quarter and full-year 2025. FOURTH QUARTER 2025 HIGHLIGHTS(As compared to the fourth quarter of 2024)Total revenue of $30.5 million, -14.4% y/yGross profit of $8.1 million, -6.8% y/yGross margin of 26.7%, +210 bps y/yOperating loss of $0.7 million and net loss attributable to shareholders of $2.6 millionAdjusted operating loss of $0.7 million1Adjusted net loss of $0.6 millionFUL

    4/9/26 4:15:00 PM ET
    $FGI
    Industrial Specialties
    Industrials

    FGI INDUSTRIES ANNOUNCES FOURTH QUARTER AND FULL-YEAR RESULTS CONFERENCE CALL DATE

    EAST HANOVER, N.J., April 6, 2026 /PRNewswire/ -- FGI Industries Ltd. (NASDAQ:FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced that it will issue financial results for the fourth quarter and full-year 2025 after the market close on Thursday, April 9, 2026. Management will conduct a conference call on Friday, April 10, 2026, at 9:00 am Eastern Time to discuss the quarterly and full-year results. A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of the C

    4/6/26 6:31:00 PM ET
    $FGI
    Industrial Specialties
    Industrials

    FGI INDUSTRIES ANNOUNCES POSTPONEMENT OF Q4 AND 2025 RESULTS CONFERENCE CALL

    EAST HANOVER, N.J., March 24, 2026 /PRNewswire/ -- FGI Industries Ltd. (NASDAQ:FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced that it has postponed the release of its financial results for the fourth quarter and year ended December 31, 2025, which was previously scheduled for Tuesday March 24, 2026. The Company is also postponing the earnings conference call originally scheduled for Wednesday, March 25, 2026, at 9:00 am Eastern Time. The Company requires additional time to complete its fourth quarter and full year financial reporting processes. The Company will announce a new date and time for the issuance of its earnings release and co

    3/24/26 4:30:00 PM ET
    $FGI
    Industrial Specialties
    Industrials

    $CGRN
    $DPSI
    $FGI
    $GIFI
    Leadership Updates

    Live Leadership Updates

    View All

    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

    Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

    6/24/25 8:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

    Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

    3/25/25 8:46:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

    Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

    11/14/24 4:05:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care